NR1H4 and diabetic kidney disease: BAs, such as tauroursodeoxycholic acid (TUDCA), exert their effects on the immunity by increasing the bile acid receptor Gpbar1 (TGR5) and farnesoid X receptor (FXR), thereby delaying the progression of DKD [117].